12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday’s pre-market session. The company’s market cap stands…
INmune Bio To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes
INmune Bio Inc. Raises ~$4.8M In Gross Proceeds Through Registered Direct Offering With Officers, Employees And Directors Purchasing ~20% Of The Offering
INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced today that
INmune Bio Inc. Presents Data On INB03’s Role As An Immune Check Point Modulator In The Treatment Of High-Risk Breast Cancer At AACR 2024
Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast CancerBoca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- INmune
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell
• Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
A Preview Of INmune Bio’s Earnings
INmune Bio (NASDAQ:INMB) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here’s what investors…
On Jan 16, Elevai Labs Inc Entered Into A License Agreement With INmune Bio, Inc.; INmune Granted The Co Certain Worldwide Exclusive And Non-Exclusive License Rights To Develop, Manufacture, And Commercialize INmunes’s EMx Technology
- SEC Filing On January 16, 2023, Elevai Labs, Inc., a Delaware corporation (the "Company"), entered into a License Agreement (the "License Agreement") with INmune Bio, Inc., a Nevada corporation ("INmune"). Under
Why Elevai Labs Stock Is Trading Higher
Elevai Labs, Inc. (NASDAQ:ELAB) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc. (NASDAQ:INMB).
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is presenting
INmune Bio Inc. Announces Expansion Of Phase II Clinical Trial For Alzheimer’s Disease In Europe; The Company Received A Cash Refund Of ~$2.8M Pursuant To An Australian Research And Development Tax Incentive
The Company received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive.Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB)